George Yankey
Interventional Cardiology · Columbia, SCNPI 1902292683
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.7%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Medtronic at 51.1% of the total. Reporting peaked in 2022 at $19,369 and has fallen 65.6% since, to $6,655 in 2025.
Across 316 payments — averaging $130.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Boston Scientific$6K
- Edwards Lifesciences$5K
- Abbott$4K
- W. L. Gore & Associates, Inc.$2K
- Abiomed$2K
- plus $2K from 20 others
What the payments were for
- Grants$15,00036%
- Travel & lodging$8,91722%
- Food & beverage$17,22442%
- Education$1920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 66 | $21,133 |
| Boston Scientific | 84 | $5,540 |
| Edwards Lifesciences | 49 | $5,005 |
| Abbott | 36 | $3,985 |
| W. L. Gore & Associates, Inc. | 16 | $1,753 |
| Abiomed | 22 | $1,542 |
| Recor Medical Inc | 6 | $670 |
| Shockwave Medical, Inc | 2 | $228 |
| Novo Nordisk | 2 | $224 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $166 |
| Acist Medical Systems, Inc. | 3 | $161 |
| Kestra Medical Technology Services, Inc. | 4 | $145 |
| Heartflow, Inc. | 1 | $133 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Novartis | 6 | $114 |
| AstraZeneca | 1 | $74 |
| Inari Medical, Inc. | 1 | $71 |
| Cardiva Medical, Inc. | 3 | $61 |
| Cordis US CORP. | 2 | $36 |
| Bayer | 2 | $31 |
| Biotronik Inc. | 1 | $30 |
| Philips North America LLC | 1 | $26 |
| Irhythm Technologies, Inc. | 1 | $25 |
| Amgen | 1 | $22 |
| Terumo Medical Corporation | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$4,139
- MitraClip$2,170
- AVVIGO Guidance System$1,322
- PASCAL$1,262
- GORE CARDIOFORM Septal Occluder$1,237
- Impella$1,039
- WATCHMAN Access System$787
- SAPIEN 3 Ultra RESILIA$525
- Paradise Ultrasound Renal Denervation System$427
- Edwards SAPIEN 3 Transcatheter Heart Valve$366
- WATCHMAN FLX$288
- Ozempic$224
- NAVITOR$199
- GENERAL - STRUCTURAL HEART$171
- OPTICROSS$167
- ROTAPRO$146
- PARADISE RENAL DENERVATION SYSTEM$145
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$142
- SelectSecure$137
- FFRct$133
How this compares
$41,333 in reported general payments places this provider in the 85th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 47 | $37,141 |
| EntrestoSacubitril/Valsartan | 36 | $32,974 |
| EliquisApixaban | 40 | $28,967 |
| BrilintaTicagrelor | 25 | $11,079 |
| ClopidogrelClopidogrel Bisulfate | 101 | $1,037 |
| Atorvastatin Calcium | 96 | $726 |
| Metoprolol Succinate | 73 | $703 |
| Prasugrel Hcl | 25 | $599 |
| Spironolactone | 66 | $288 |
| Torsemide | 16 | $252 |
| Pantoprazole Sodium | 24 | $249 |
| Potassium Chloride | 11 | $183 |
| Chlorthalidone | 13 | $178 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 14 | $165 |
| Amlodipine Besylate | 58 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $114 | $32,97436 claims |
| AstraZenecaBrilinta | $74 | $11,07925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Columbia
- Michael CryerColumbia$92K
- Loren MorganColumbia$60K
- Vince VismaraColumbia$60K
- Patrick HallColumbia$50K
- Michael FosterColumbia$23K
- Matthew CantrellColumbia$21K
- Christopher HuffmanColumbia$21K
- Gopi ShahColumbia$16K
- Katrina BidwellColumbia$15K
- Guillermo PinedaColumbia$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.